Table V.
CBXs regulating malignant phenotype changes in tumors through ncRNA interactions.
| Cancer type | Malignant phenotype changes | ncRNA interactions | (Refs.) |
|---|---|---|---|
| PAAD | Proliferation; migration; invasion | lncRNA PCAT6/miR-185-5p/CBX2 | (144) |
| UBC | Proliferation | lncRNA CASC9/miR-497-5p/CBX2 | (145) |
| NEPC | Proliferation; metastases | LINC00261/miR-8485/CBX2/FOXA2 | (146) |
| OC | Proliferation; apoptosis; migration; invasion | miR-342-5p/CBX2/Wnt/β-catenin | (147) |
| Osteosarcoma | Proliferation; growth; invasion | miRNA let-7a/CBX2 | (148) |
| OC | Proliferation; apoptosis; migration; invasion; chemosensitivity | circ_0061140/miR-136/CBX2 | (149) |
| Glioma | Proliferation; migration; invasion; self-renewal | lncRNA RP11-279C4.1/miR-1273g-3p/CBX3 | (150) |
| HCC | Proliferation; apoptosis; migration; invasion | lncRNA KCNQ1OT1/miR-29a-3p/CBX3 | (151) |
| HCC | Proliferation; migration; invasion | LINC01006/miR-433-3/CBX3 | (152) |
| COAD | Proliferation; migration; invasion | lncRNA SNHG17/miR-375/CBX3 | (153) |
| DLBCL | Proliferation; apoptosis | LINC00857/miR-370-3p/CBX3 | (154) |
| Glioma | Proliferation; cell cycle | LINC00998/CBX3/c-Met/AKT/mTOR | (155) |
| HCC | Growth; migration; invasion | miR-139/CBX3 | (156) |
| CRC | Proliferation; growth | miR-30a/CBX3/CDKN1A | (157) |
| Glioma | Growth; apoptosis; migration; invasion | circ_EZH2/miR-1265/CBX3 | (158) |
| NSCLC | Proliferation | lncRNA SNHG5/miR-181c-5p/CBX4 | (159) |
| GC | Proliferation | LINC00265/miR-144-3p/CBX4 | (160) |
| CCA | Proliferation; migration; invasion | lncRNA FOXP4-AS1/miR-136-5p/CBX4 | (161) |
| PCa | Proliferation; migration; invasion | lncRNA RAMS11/CBX4/TOP2α | (162) |
| BC | Proliferation | miR-129-5p/CBX4 | (163) |
| BC | Proliferation; migration; invasion | miR-515-5p/CBX4 | (164) |
| GC | Proliferation; apoptosis; invasion | miR-507/CBX4/Wnt/β-catenin/HIF-1α | (165) |
| HCC | Proliferation; metastases; angiogenesis; self-renewal | miR-6838-5p/CBX4/ERK | (166) |
| CCA | Proliferation; cell cycle | miR-497-5p/CBX4 | (167) |
| ACP | Osteoblast differentiation and calcium deposition | BMP2/miR-181b/CBX4/HDAC3/RUNX2 | (168) |
| LC | Proliferation; migration; invasion | circ_PVT1/miR-21-5p/CBX4/Wnt4/β-catenin | (170) |
| BC | Proliferation; migration | CBX4/miR-137/Notch1 | (76) |
| HCC | Proliferation; stemness | miR-424/CBX4/YAP1 | (169) |
| BC | Proliferation; migration; invasion | circ_0008039/miR-515-5p/CBX4 | (171) |
| Glioma | Proliferation; apoptosis | LINC02381/CEBPβ/CBX5 | (172) |
| BC | Proliferation; migration | lncRNA SNHG11/miR-2355-5p/CBX5 | (173) |
| HCC | Proliferation | miR-675/CBX5/EGR1/H19/PKM2 | (174) |
| HCC | Stemness | miR-675/PKM2/CBX5/c-Myc | (175) |
| RCC | Proliferation; migration | lncRNA LOXL1-AS1/miR-589-5p/CBX5 | (176) |
| RCC | Proliferation; migration; invasion | circ_0037866/miR-384/CBX5 | (177) |
| HCC | Proliferation; migration; invasion | lncRNA MIR100HG/miR-146b-5p/CBX6 | (178) |
| LUAD | Proliferation; migration | lnc RNA SNHG7/miR-181/CBX7/Wnt/β-catenin | (179) |
| NSCLC | Proliferation; migration; invasion | miRNA-19/CBX7 | (180) |
| UBC | Invasion | miR-9/CBX7 | (181) |
| PCa | Proliferation; migration; invasion | miR-375/CBX7 | (182) |
| OC | Proliferation; migration; invasion; EMT | miR-18a/CBX7/ERK/MAPK | (183) |
| BC | Proliferation; cell cycle | HMGA1/CBX7/miR-181b | (184) |
| PCa | Proliferation; cell cycle; apoptosis | circ_GOLPH3/CBX7 | (185) |
| HCC | Growth; migration | CBX8/EGR1/miR-365-3p/AKT/β-catenin | (121) |
| CC | Proliferation; apoptosis; migration; invasion | CBX8/miR-378a-3p/PDIA4/caspase 3/caspase 7 | (186) |
| DLBCL | Proliferation; apoptosis | miR-429/CBX8 | (187) |
| BC | Proliferation; migration; invasion | circ_0005230/miR-618/CBX8 | (188) |
| CCA | Proliferation; migration; invasion | circ_8924/miR-518d-5p/519-5p/CBX8 | (189) |
CBX, chromobox; PAAD, pancreatic adenocarcinoma; UBC, urinary bladder cancer; NEPC, neuroendocrine prostate cancer; OC, ovarian cancer; HCC, hepatocellular carcinoma; COAD, colon adenocarcinoma; DLBCL, diffuse large B-cell lymphoma; CRC, colorectal cancer; NSCLC, non-small cell lung cancer; GC, gastric cancer; CCA, cervical carcinoma; PCa, prostate carcinoma; BC, breast cancer; ACP, adamantinomatous craniopharyngioma; LC, laryngocarcinoma; RCC, renal cell carcinoma; LUAD, lung adenocarcinoma; CC, colon cancer; EMT, epithelial to mesenchymal transition; ncRNA, noncoding RNA; lncRNA, long noncoding RNA; miR, microRNA; circ, circular RNA; PCAT6, prostate cancer associated transcript 6; CASC9, cancer susceptibility 9; FOXA2, forkhead box A2; KCNQ1OT1, KCNQ1 opposite strand/antisense transcript 1; SNHG, small nucleolar RNA host gene; CDKN1A, cyclin dependent kinase inhibitor 1A; EZH2, enhancer of zeste homolog 2; FOXP4-AS1, forkhead box P4 antisense RNA 1; RAMS11, RNA associated with metastasis-11; TOP2α, topoisomerase IIα; HIF-1α, hypoxia-inducible factor-1α; ERK, extracellular signal-regulated kinase; BMP2, bone morphogenetic protein 2; HDAC, histone deacetylase; RUNX2, runt-related transcription factor 2; YAP1, Yes-associated protein 1; CEBPβ, CCAAT/enhancer-binding protein β; EGR1, early growth response 1; PKM2, pyruvate kinase M2; LOXL1-AS1, lysyl oxidase like 1 antisense RNA 1; MAPK, mitogen-activated protein kinase; HMGA1, high mobility group AT-hook 1; GOLPH3, Golgi phosphoprotein 3; PDIA4, protein disulfide-isomerase A4.